Business Context and Reporting Period
Company: Tempest Therapeutics, Inc. (TPST)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2025
Business Overview: Tempest is a clinical-stage biotechnology company focused on developing targeted and immune-mediated therapies for cancer. Its lead program, amezalpat (TPST-1120), is advancing toward a pivotal Phase 3 study for first-line hepatocellular carcinoma (HCC). A second candidate, TPST-1495, is in development for Familial Adenomatous Polyposis (FAP).
Recent Corporate Actions: The Company effected a 1-for-13 reverse stock split on April 8, 2025. All share and per-share data in this filing have been retroactively adjusted to reflect this split.
Key Financial Metrics
| Metric (in thousands) | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(10,860) | $(7,904) |
| Net Loss Per Share (Basic & Diluted) | $(3.16) | $(4.62) |
| Research & Development Expenses | $7,627 | $4,340 |
| General & Administrative Expenses | $3,309 | $3,634 |
| Cash and Cash Equivalents (End of Period) | $21,511 | $32,769 |
| Accumulated Deficit | $(217,966) | $(173,167) |
| Current Loan Payable (Net) | $4,190 | $6,354 |
Note: The Company has no operating revenue. Expenses are primarily driven by clinical development activities.
Material Changes vs. Prior Period
- Increased Net Loss: Net loss increased by approximately 37% to $10.9 million, driven primarily by a 76% increase in R&D expenses.
- R&D Spend Surge: R&D expenses rose to $7.6 million from $4.3 million year-over-year. This increase is attributed to costs associated with engaging contract research and manufacturing organizations (CROs/CMOs) in preparation for the pivotal Phase 3 trial of amezalpat.
- Cash Burn: Cash used in operating activities was $8.0 million for Q1 2025, compared to $7.2 million in Q1 2024. Total cash and cash equivalents decreased by $8.8 million during the quarter.
- Debt Reduction: The Company made principal payments on its Oxford Finance loan, reducing the current loan payable balance from $6.4 million to $4.2 million during the quarter.
Guidance, Outlook, Risks, and Unusual Items
Going Concern and Liquidity
The Company has raised substantial doubt regarding its ability to continue as a going concern. As of March 31, 2025, cash resources of $21.5 million, combined with net proceeds from the At-The-Market (ATM) program, are projected to fund operations for less than 12 months. The Company is exploring strategic alternatives (mergers, acquisitions, partnerships) to maximize stockholder value and secure additional funding.
Strategic Review and Restructuring
- Strategic Alternatives: In April 2025, the Company announced a strategic review process, retaining MTS Health Partners, L.P. as a financial advisor.
- Workforce Reduction: Effective April 30, 2025, the Company reduced its workforce by 21 of 26 full-time employees. The Company estimates $1.5 million in cash severance and related costs, primarily to be incurred in Q2 2025.
- Debt Repayment: On April 8, 2025 (subsequent to the reporting period), the Company repaid the remaining $3.5 million principal and accrued interest on its Oxford Finance loan in full, terminating the agreement and releasing all liens.
Regulatory and Clinical Outlook
- Amezalpat: Received FDA Fast Track Designation and Orphan Drug Designation for HCC in early 2025. The Company received a "Study May Proceed" letter for its pivotal Phase 3 trial.
- TPST-1495: Received FDA authorization to initiate an NCI-funded Phase 2 trial in FAP, expected to begin in 2025.
Risks
Key risks include the inability to secure additional financing, failure of strategic alternatives, potential wind-down of operations, and the inherent uncertainties of clinical development and regulatory approval.
Investor Verification Checklist
- Cash Runway: Verify the updated cash runway following the April 2025 workforce reduction and the full repayment of the Oxford Finance loan.
- Strategic Process: Monitor for updates on the strategic review process and the engagement of MTS Health Partners to determine if a transaction is imminent.
- ATM Program Capacity: Confirm the remaining capacity under the At-The-Market offering program, noting the "baby shelf" limitations due to public float being under $75 million.
- Severance Costs: Track the actual cash outflow for the $1.5 million estimated severance package in Q2 2025 financials.
- Reverse Stock Split Impact: Assess the impact of the 1-for-13 reverse stock split on trading liquidity and share price stability.